Base de dados : MEDLINE
Pesquisa : D02.705.629.500 [Categoria DeCS]
Referências encontradas : 413 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 42 ir para página                         

  1 / 413 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28045910
[Au] Autor:Huang R; Feng Y; Wang Y; Qin X; Melgiri ND; Sun Y; Li X
[Ad] Endereço:Department of Rehabilitation Medicine, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
[Ti] Título:Comparative Efficacy and Safety of Antihypertensive Agents for Adult Diabetic Patients with Microalbuminuric Kidney Disease: A Network Meta-Analysis.
[So] Source:PLoS One;12(1):e0168582, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Antihypertensive treatment mitigates the progression of chronic kidney disease. Here, we comparatively assessed the effects of antihypertensive agents in normotensive and hypertensive diabetic patients with microalbuminuric kidney disease. METHODS: MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were systematically searched for randomized controlled trials (RCTs) comparing oral antihypertensive agents in adult diabetic patients with microalbuminuria. The primary efficacy outcome was reduction in albuminuria, and the primary safety outcomes were dry cough, presyncope, and edema. Random-effects pairwise and Bayesian network meta-analyses were performed to produce outcome estimates for all RCTs, only hypertensive RCTs, or only normotensive RCTs. Surface under the cumulative ranking (SUCRA) probability rankings were calculated for all outcomes. Sensitivity analyses on type 2 diabetes status, age, or follow-up duration were also performed. RESULTS: A total of 38 RCTs were included in the meta-analyses. The angiotensin-converting enzyme inhibitor-calcium channel blocker (ACEI-CCB) combination therapy of captopril+diltiazem was most efficacious in reducing albuminuria irrespective of blood pressure status. However, the ACEI-angiotensin receptor blocker (ACEI-ARB) combination therapy of trandolapril+candesartan was the most efficacious in reducing albuminuria for normotensive patients, while the ACEI-CCB combination therapy of fosinopril+amlodipine was the most efficacious in reducing albuminuria for hypertensive patients. The foregoing combination therapies displayed inferior safety profiles relative to ACEI monotherapy with respect to dry cough, presyncope, and edema. With respect to type 2 diabetic patients with microalbuminuria, the Chinese herbal medicine Tangshen formula followed by the ACEI ramipril were the most efficacious in reducing albuminuria. CONCLUSIONS: Trandolapril+candesartan appears to be the most efficacious intervention for reducing albuminuria for normotensive patients, while fosinopril+amlodipine appears to be the most efficacious intervention for reducing albuminuria for hypertensive patients. For practitioners opting for monotherapy, our SUCRA analysis supports the use of trandolapril and fosinopril in normotensive and hypertensive adult diabetic patients with microalbuminuria, respectively.
[Mh] Termos MeSH primário: Albuminúria/tratamento farmacológico
Anti-Hipertensivos/uso terapêutico
Diabetes Mellitus Tipo 2/terapia
Nefropatias/terapia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Inibidores da Enzima Conversora de Angiotensina/farmacologia
Teorema de Bayes
Benzimidazóis/administração & dosagem
Seguimentos
Fosinopril/administração & dosagem
Seres Humanos
Hipertensão/tratamento farmacológico
Indóis/administração & dosagem
Nefropatias/complicações
Meia-Idade
Segurança do Paciente
Probabilidade
Ensaios Clínicos Controlados Aleatórios como Assunto
Tetrazóis/administração & dosagem
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; META-ANALYSIS
[Nm] Nome de substância:
0 (Angiotensin-Converting Enzyme Inhibitors); 0 (Antihypertensive Agents); 0 (Benzimidazoles); 0 (Indoles); 0 (Tetrazoles); 1T0N3G9CRC (trandolapril); R43D2573WO (Fosinopril); S8Q36MD2XX (candesartan)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170821
[Lr] Data última revisão:
170821
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170104
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0168582


  2 / 413 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
[PMID]:26617877
[Au] Autor:Huang H; Hu L; Lin J; Zhu X; Cui W; Xu W
[Ad] Endereço:Department of Internal Medicine, The Eastern Hospital of First Affiliated Hospital, Sun Yat-Sen University Guangzhou 510700, China.
[Ti] Título:Effect of fosinopril on chemerin and VEGF expression in diabetic nephropathy rats.
[So] Source:Int J Clin Exp Pathol;8(9):11470-4, 2015.
[Is] ISSN:1936-2625
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:As the most common and severe complication of diabetes, diabetic nephropathy (DN) has been known to be related with angiotensin converting enzyme inhibitor (ACEI), which can reduce proteinuria and protect renal function. This study analyzed the effect of ACEI analog-fosinopril-on the expression of chemerin and vascular epithelial growth factor (VEGF), in an attempt to reveal the mechanism of ACEI analog on renal protection. A total of 45 SD rats were induced by sreptozotocin for diabetes and were given fosinopril via intragastric cannulation for 12 weeks. After sacrifice, serum and renal chemerin and VEGF contents were quantified by enzyme linked immunosorbent assay (ELISA) and Western blot method, in addition to biochemical laboratory examinations. In diabetic model rats, blood glucose, creatinine, urea nitrogen, 24-hour urinary protein, chemerin and VEGF protein contents were all significantly elevated when compared to those in control group (P<0.05). After fosinopril treatment, blood creatinine, urea nitrogen, 24-hour urinary protein, Chemerin and VEGF protein concentrations were significantly depressed (P<0.05 compared to model group). Positive relationships existed between renal chemerin, VEGF and urea protein levels. Fosinopril may protect renal tissues in diabetes by suppressing chemerin and VEGF protein expression.
[Mh] Termos MeSH primário: Inibidores da Enzima Conversora de Angiotensina/farmacologia
Quimiocinas/biossíntese
Nefropatias Diabéticas/metabolismo
Fosinopril/farmacologia
Peptídeos e Proteínas de Sinalização Intercelular/biossíntese
Rim/efeitos dos fármacos
Fator A de Crescimento do Endotélio Vascular/biossíntese
[Mh] Termos MeSH secundário: Animais
Western Blotting
Quimiocinas/efeitos dos fármacos
Diabetes Mellitus Experimental
Ensaio de Imunoadsorção Enzimática
Masculino
Ratos
Fator A de Crescimento do Endotélio Vascular/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Angiotensin-Converting Enzyme Inhibitors); 0 (Chemokines); 0 (Intercellular Signaling Peptides and Proteins); 0 (Vascular Endothelial Growth Factor A); 0 (chemerin protein, human); R43D2573WO (Fosinopril)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151201
[St] Status:MEDLINE


  3 / 413 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26382240
[Au] Autor:Weir MA; Fleet JL; Dixon SN; Jain AK; Oliver M; Wald R; McIntyre C; Garg AX
[Ad] Endereço:Department of Medicine, Division of Nephrology, Western University, London, Ont., Canada.
[Ti] Título:Angiotensin Converting Enzyme Inhibitor Dialyzability and Outcomes in Older Patients Receiving Hemodialysis.
[So] Source:Blood Purif;40(3):232-42, 2015.
[Is] ISSN:1421-9735
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIMS: Some angiotensin converting enzyme (ACE) inhibitors are efficiently removed from circulation by hemodialysis ('high dialyzability'), whereas others are not ('low dialyzability'). In patients receiving hemodialysis, this may influence the effectiveness of ACE inhibitors. METHODS: Using linked healthcare databases we identified older patients receiving chronic hemodialysis who filled new ACE inhibitor prescriptions. The low dialyzability group (n = 3,369) included fosinopril and ramipril. The high dialyzability group (n = 5,974) included enalapril, lisinopril, and perindopril. The primary outcome was all-cause mortality within 180 days of first ACE inhibitor prescription. RESULTS: There were 361 deaths among 5,974 patients (6.0%) prescribed with low dialyzability ACE inhibitors and 179 deaths among 3,369 patients (5.3%) prescribed with high dialyzability ACE inhibitors (relative risk 1.1, 95% CI 0.9-1.3, p = 0.6). CONCLUSION: In this study of older patients receiving hemodialysis, the dialyzability of ACE inhibitors was not associated with mortality or cardiovascular outcomes.
[Mh] Termos MeSH primário: Inibidores da Enzima Conversora de Angiotensina/uso terapêutico
Cardiotônicos/uso terapêutico
Doenças Cardiovasculares/sangue
Falência Renal Crônica/sangue
Diálise Renal/métodos
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Inibidores da Enzima Conversora de Angiotensina/sangue
Inibidores da Enzima Conversora de Angiotensina/farmacocinética
Cardiotônicos/sangue
Cardiotônicos/farmacocinética
Doenças Cardiovasculares/complicações
Doenças Cardiovasculares/mortalidade
Doenças Cardiovasculares/terapia
Enalapril/sangue
Enalapril/farmacocinética
Enalapril/uso terapêutico
Feminino
Fosinopril/sangue
Fosinopril/farmacocinética
Fosinopril/uso terapêutico
Hemorreologia
Seres Humanos
Falência Renal Crônica/complicações
Falência Renal Crônica/mortalidade
Falência Renal Crônica/terapia
Rins Artificiais
Lisinopril/sangue
Lisinopril/farmacocinética
Lisinopril/uso terapêutico
Masculino
Meia-Idade
Perindopril/sangue
Perindopril/farmacocinética
Perindopril/uso terapêutico
Ramipril/sangue
Ramipril/farmacocinética
Ramipril/uso terapêutico
Diálise Renal/instrumentação
Estudos Retrospectivos
Análise de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Angiotensin-Converting Enzyme Inhibitors); 0 (Cardiotonic Agents); 69PN84IO1A (Enalapril); E7199S1YWR (Lisinopril); L35JN3I7SJ (Ramipril); R43D2573WO (Fosinopril); Y5GMK36KGY (Perindopril)
[Em] Mês de entrada:1607
[Cu] Atualização por classe:151008
[Lr] Data última revisão:
151008
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150919
[St] Status:MEDLINE
[do] DOI:10.1159/000438821


  4 / 413 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26349482
[Au] Autor:Araiza-Saldaña CI; Pedraza-Priego EF; Torres-López JE; Rocha-González HI; Castañeda-Corral G; Hong-Chong E; Granados-Soto V
[Ad] Endereço:División Académica de Ciencias de la Salud, Universidad Juárez Autónoma de Tabasco, Villahermosa, Tabasco, Mexico.
[Ti] Título:Fosinopril Prevents the Development of Tactile Allodynia in a Streptozotocin-Induced Diabetic Rat Model.
[So] Source:Drug Dev Res;76(8):442-9, 2015 Dec.
[Is] ISSN:1098-2299
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The aim of this study was to evaluate fosinopril-induced changes in hemodynamic parameters and tactile allodynia in a rat model of diabetes. Diabetes was induced by streptozotocin (STZ; 50 mg/kg, i.p.) in male Wistar rats. STZ produced hyperglycemia, weight loss, polydipsia, polyphagia, and polyuria as well as long-term arterial hypotension, bradycardia, and tactile allodynia at 10-12 weeks. Daily administration of the angiotensin converting enzyme inhibitor, fosinopril (25 mg/kg, p.o., for 11 weeks) partially reduced the loss of body weight, decreased hyperglycemia, and systolic blood pressure in diabetic rats. Likewise, systemic administration of fosinopril prevented the development and maintenance of tactile allodynia in STZ-induced diabetic rats. These data suggest that fosinopril may have a role in the pharmacotherapy of diabetic neuropathic pain.
[Mh] Termos MeSH primário: Inibidores da Enzima Conversora de Angiotensina/farmacologia
Diabetes Mellitus Experimental/tratamento farmacológico
Fosinopril/farmacologia
Hiperalgesia/prevenção & controle
[Mh] Termos MeSH secundário: Animais
Diabetes Mellitus Experimental/sangue
Diabetes Mellitus Experimental/induzido quimicamente
Diabetes Mellitus Experimental/fisiopatologia
Neuropatias Diabéticas/sangue
Neuropatias Diabéticas/tratamento farmacológico
Neuropatias Diabéticas/fisiopatologia
Hemodinâmica/efeitos dos fármacos
Hiperalgesia/sangue
Hiperalgesia/fisiopatologia
Hiperglicemia/sangue
Hiperglicemia/induzido quimicamente
Hiperglicemia/tratamento farmacológico
Hiperglicemia/fisiopatologia
Insulina/sangue
Masculino
Ratos
Ratos Wistar
Perda de Peso/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Angiotensin-Converting Enzyme Inhibitors); 0 (Insulin); R43D2573WO (Fosinopril)
[Em] Mês de entrada:1606
[Cu] Atualização por classe:160115
[Lr] Data última revisão:
160115
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150910
[St] Status:MEDLINE
[do] DOI:10.1002/ddr.21280


  5 / 413 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25875586
[Au] Autor:Xue K; Li G; Sun X; Hu Y; Hu L; Huang J; Si L
[Ad] Endereço:Department of Pharmaceutics, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China.
[Ti] Título:Simultaneous quantification of fosinopril and its active metabolite fosinoprilat in rat plasma by UFLC-MS/MS: Application of formic acid in the stabilization of an ester-containing drug.
[So] Source:J Chromatogr B Analyt Technol Biomed Life Sci;990:141-9, 2015 May 15.
[Is] ISSN:1873-376X
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Fosinopril is an angiotensin-converting enzyme inhibitor containing a phosphate ester group which undergoes esterase hydrolysis to its active metabolite, fosinoprilat. EDTA was utilized as an anticoagulant to inhibit the hydrolysis of fosinopril in whole blood during blood collection and processing. To prevent the ex vivo conversion to fosinoprilat, formic acid was added to rat plasma to effectively stabilize fosinopril. A sensitive, rapid and robust ultra-fast liquid chromatography-tandem mass spectrometry (UFLC-MS/MS) method was developed and validated for simultaneous determination of fosinopril and fosinoprilat in rat plasma. Protein precipitation was employed for plasma sample clean-up. Chromatographic separation was achieved on a Welch Ultimate XB-C18 column using gradient elution with a total run time of 5min. Analytes and their stable isotope labeled internal standards were detected by positive ion electrospray tandem mass spectrometric assay. The assay involves quantitation of both analytes in small-volume (50µL) plasma, with the lower limit of quantification of 0.1 and 1ng/mL for fosinopril and fosinoprilat, respectively. The method was fully validated in linear calibration ranges of 0.1-150ng/mL for fosinopril and 1-1500ng/mL for fosinoprilat with acceptable accuracy and precision. Assay recoveries were high (>95% for fosinopril and >91% for fosinoprilat) and matrix effect was negligible. Both analytes were found to be stable in stabilized rat plasma for 6h at room temperature, 30 days at -80°C, and following three freeze-thaw cycles and were also stable in processed samples for 36h at 4°C. The validated method was successfully applied to sample analyses for pharmacokinetic study of fosinopril and can be extended to the measurement of fosinopril in other biological samples.
[Mh] Termos MeSH primário: Cromatografia Líquida de Alta Pressão/métodos
Formiatos/química
Fosinopril/análogos & derivados
Fosinopril/sangue
Espectrometria de Massas em Tandem/métodos
[Mh] Termos MeSH secundário: Animais
Estabilidade de Medicamentos
Modelos Lineares
Ratos
Ratos Sprague-Dawley
Reprodutibilidade dos Testes
Sensibilidade e Especificidade
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Formates); 0YIW783RG1 (formic acid); R43D2573WO (Fosinopril); S312EY6ZT8 (fosinoprilat)
[Em] Mês de entrada:1601
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150416
[St] Status:MEDLINE


  6 / 413 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25033012
[Au] Autor:Reeder MJ; Wood GS
[Ad] Endereço:Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison, WI.
[Ti] Título:Drug-induced pseudo-Sezary syndrome: a case report and literature review.
[So] Source:Am J Dermatopathol;37(1):83-6, 2015 Jan.
[Is] ISSN:1533-0311
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Pseudo-Sezary syndrome is a benign lymphoproliferative disorder, which clinically and pathologically mimics true Sezary syndrome. In this article, a case of pseudo-Sezary syndrome and review the literature has been reported. The patient was a 51-year-old man who developed erythroderma and palmoplantar keratoderma. The patient's medication history included fosinopril and combination metoprolol/hydrochlorothiazide. Flow cytometry showed a population of 2500 "Sezary-like" CD4726 T cells per microliter in the peripheral blood. Skin biopsy showed numerous atypical lymphocytes with epidermotropism, and there was matching dominant T-cell clonality in the skin and peripheral blood. After stopping all antihypertensive medications, the eruption resolved in its entirety.
[Mh] Termos MeSH primário: Anti-Hipertensivos/efeitos adversos
Erupção por Droga/etiologia
Síndrome de Sézary/diagnóstico
Neoplasias Cutâneas/diagnóstico
Pele/efeitos dos fármacos
Linfócitos T/efeitos dos fármacos
[Mh] Termos MeSH secundário: Antagonistas de Receptores Adrenérgicos beta 1/efeitos adversos
Inibidores da Enzima Conversora de Angiotensina/efeitos adversos
Biomarcadores/análise
Biópsia
Diagnóstico Diferencial
Diuréticos/efeitos adversos
Erupção por Droga/genética
Erupção por Droga/imunologia
Erupção por Droga/patologia
Citometria de Fluxo
Fosinopril/efeitos adversos
Genes Codificadores dos Receptores de Linfócitos T
Seres Humanos
Hidroclorotiazida/efeitos adversos
Imuno-Histoquímica
Masculino
Metoprolol/efeitos adversos
Meia-Idade
Valor Preditivo dos Testes
Prognóstico
Síndrome de Sézary/genética
Síndrome de Sézary/imunologia
Síndrome de Sézary/patologia
Pele/imunologia
Pele/patologia
Neoplasias Cutâneas/genética
Neoplasias Cutâneas/imunologia
Neoplasias Cutâneas/patologia
Linfócitos T/imunologia
Linfócitos T/patologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.; REVIEW
[Nm] Nome de substância:
0 (Adrenergic beta-1 Receptor Antagonists); 0 (Angiotensin-Converting Enzyme Inhibitors); 0 (Antihypertensive Agents); 0 (Biomarkers); 0 (Diuretics); 0J48LPH2TH (Hydrochlorothiazide); GEB06NHM23 (Metoprolol); R43D2573WO (Fosinopril)
[Em] Mês de entrada:1507
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140718
[St] Status:MEDLINE
[do] DOI:10.1097/DAD.0000000000000169


  7 / 413 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:26492775
[Au] Autor:Agayev MM
[Ti] Título:[CLINICAL PERSPECTIVES OF COMPLEX APPLICATION OF PERCUTANEOUS CORONARY INTERVENTION AND DRUG REVASCULARIZATION IN ACUTE CORONARY SYNDROME].
[So] Source:Lik Sprava;(9-10):46-56, 2014 Sep-Oct.
[Is] ISSN:1019-5297
[Cp] País de publicação:Ukraine
[La] Idioma:rus
[Ab] Resumo:The article presents the evaluation of the influence of complex application of monopril, propranolol and heparin and percutaneous coronary intervention (PCI); monopril, propranolol with methylase in combination with PCI and PCI only on hemddynamics, cardiohemodynamics and clinical course in acute myocardial infarction (MI), as well as the monitoring of these patients. A comparison of the results of the complex medical and mechanical revascularization. The study involved 63 patients with acute coronary syndrome (ACS): anterior MI with Q wave and ST-segment with the rise in age from 30 to 70 years, the average age (56.7 +/- 1.2) years old, who were randomly divided into three groups with 21 in each. Patients in group I received heparin, propranolol with monopril and PCI; II--methylase (tenakteplaza) and propranolol, monopril and after 1 day they performed PCI; group III patients performed only PCI. With the help of echocardiography and Doppler echocardiometry values studied endsystolic (ESV) and end-diastolic (EDV) volume, ejection fraction (EF), stroke (SI) and heart (HI) index, index of local contractility disturbance of the left ventricle (LV ILCD) as well as the dynamics of systolic, (SBP) and diastolic (PBP) blood pressure, clinical features of myocardial infarction during follow-up. Injection of methylase, infusion of propranolol, receiving per os of monopril and conduct after 1 day of PCI accelerate the stabilization of central hemodynamics. ESV, EDV and ILCD reduce, systolic function of LV improves, ejection fraction increases. When there was no restenosis, myocardial infarction relapse and mortality 1 patient on 5th day was recorded acute heart failure (AHF). When treating by monopril, propranolol and heparin and conduct of PCI also stabilize central hemodynamics. ESV, EDV and ILCD reduce, EF increases and systolic function of LV improves (I group). However, in one patient on the 3rd day were recorded acute heart failure (AHF). Restenosis, recurrent myocardial infarction, and mortality were not observed. During the PCI only treatment 4 patients relapsed MI, 4 patients had restenosis, 2 patients had AHF and 2 patients died. Observations have shown that the combined application of drug therapy with PCI provides a positive predictive as opposed to using only PCI.
[Mh] Termos MeSH primário: Síndrome Coronariana Aguda
Antagonistas Adrenérgicos beta/uso terapêutico
Fibrinolíticos/uso terapêutico
Infarto do Miocárdio
Intervenção Coronária Percutânea
[Mh] Termos MeSH secundário: Síndrome Coronariana Aguda/tratamento farmacológico
Síndrome Coronariana Aguda/cirurgia
Antagonistas Adrenérgicos beta/administração & dosagem
Adulto
Idoso
Terapia Combinada
Quimioterapia Combinada
Feminino
Fibrinolíticos/administração & dosagem
Fosinopril/administração & dosagem
Fosinopril/uso terapêutico
Hemodinâmica/efeitos dos fármacos
Heparina/administração & dosagem
Heparina/uso terapêutico
Seres Humanos
Masculino
Meia-Idade
Infarto do Miocárdio/tratamento farmacológico
Infarto do Miocárdio/cirurgia
Propranolol/administração & dosagem
Propranolol/uso terapêutico
Ativador de Plasminogênio Tecidual/administração & dosagem
Ativador de Plasminogênio Tecidual/uso terapêutico
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Adrenergic beta-Antagonists); 0 (Fibrinolytic Agents); 9005-49-6 (Heparin); 9Y8NXQ24VQ (Propranolol); EC 3.4.21.68 (Tissue Plasminogen Activator); R43D2573WO (Fosinopril); WGD229O42W (tenecteplase)
[Em] Mês de entrada:1512
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151024
[St] Status:MEDLINE


  8 / 413 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:25796845
[Au] Autor:Khukhlina OS; Mandryk OIe; Drozd VIu; Haidychuk VS; Kosar LIu
[Ti] Título:[The use of complex tools ezetimibe, hepadyfu fosinopril and correction of blood pressure and endothelial dysfunction in patients with nonalcoholic steatohepatitis and essential hypertension stage II].
[So] Source:Wiad Lek;67(2 Pt 2):269-72, 2014.
[Is] ISSN:0043-5147
[Cp] País de publicação:Poland
[La] Idioma:ukr
[Ab] Resumo:The article investigates the impact of complex tools fosinopril, hepadyf and ezetimibe for correction of functional state of the endothelium and changes in blood pressure in patients with nonalcoholic steatohepatitis, obesity and essential hypertension stage II.
[Mh] Termos MeSH primário: Adenina/uso terapêutico
Azetidinas/uso terapêutico
Carnitina/uso terapêutico
Fosinopril/uso terapêutico
Hipertensão/tratamento farmacológico
Hepatopatia Gordurosa não Alcoólica/complicações
Doenças Vasculares/tratamento farmacológico
[Mh] Termos MeSH secundário: Anticolesterolemiantes/uso terapêutico
Combinação de Medicamentos
Endotélio Vascular/efeitos dos fármacos
Hipertensão Essencial
Ezetimiba
Seres Humanos
Hipertensão/etiologia
Obesidade/complicações
Doenças Vasculares/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anticholesteremic Agents); 0 (Azetidines); 0 (Drug Combinations); EOR26LQQ24 (Ezetimibe); JAC85A2161 (Adenine); R43D2573WO (Fosinopril); S7UI8SM58A (Carnitine)
[Em] Mês de entrada:1507
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150324
[St] Status:MEDLINE


  9 / 413 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25287996
[Au] Autor:Steiner MC; Greening NJ
[Ad] Endereço:Leicester Respiratory Biomedical Research Unit, University Hospitals of Leicester NHS Trust, Leicester, England; School of Sport, Exercise and Health Sciences, Loughborough University, Leicester, England. Electronic address: michael.steiner@uhl-tr.nhs.uk.
[Ti] Título:Treating the exercise problem in COPD.
[So] Source:Chest;146(4):878-880, 2014 Oct.
[Is] ISSN:1931-3543
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Inibidores da Enzima Conversora de Angiotensina/uso terapêutico
Fosinopril/uso terapêutico
Doença Pulmonar Obstrutiva Crônica/fisiopatologia
Músculo Quadríceps/efeitos dos fármacos
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Masculino
[Pt] Tipo de publicação:COMMENT; EDITORIAL
[Nm] Nome de substância:
0 (Angiotensin-Converting Enzyme Inhibitors); R43D2573WO (Fosinopril)
[Em] Mês de entrada:1412
[Cu] Atualização por classe:170522
[Lr] Data última revisão:
170522
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:141008
[St] Status:MEDLINE


  10 / 413 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25188759
[Au] Autor:Kiselev AR; Gridnev VI; Prokhorov MD; Karavaev AS; Posnenkova OM; Ponomarenko VI; Bezruchko BP
[Ad] Endereço:Centre of New Cardiological Informational, Saratov Research Institute of Cardiology, Saratov-Russia. antonkis@list.ru.
[Ti] Título:Effects of antihypertensive treatment on cardiovascular autonomic control: a prospective study.
[So] Source:Anadolu Kardiyol Derg;14(8):701-10, 2014 Dec.
[Is] ISSN:1308-0032
[Cp] País de publicação:Turkey
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The aim of study was to propose an approach to the control of dynamics of autonomic dysfunction in cardiovascular system (CVS) under antihypertensive treatment (AT) in patients with arterial hypertension (AH), based on individual features of synchronization of 0.1-Hz rhythms in heart rate (HR) and photoplethysmogram (PPG) and spectral indices of heart rate variability (HRV). METHODS: We designed prospective cohort diagnostic accuracy and studied 105 AH patients (66 females) aged 47±8 years during 8 weeks. The HRV spectral indices and the index S of synchronization between the 0.1-Hz rhythms in HR and PPG during a tilt test are compared in their ability to control the AT with angiotensin-converting enzyme inhibitors (ACE-Is) (fosinopril or enalapril) and ß-blockers (atenolol or metoprolol). We apply Shapiro-Wilk, Mann-Whitney U and Wilcoxon tests. RESULTS: It is shown that the power of low-frequency (LF) band in HRV spectrum and index S can be used as criteria for initial assessment of the status of autonomic regulation in AH patients. The patients with S<25% in vertical body's position and LF>250 ms2 in horizontal body's position require ACE-Is treatment. The AH patients with LF<350 ms2 and S<30% in vertical body's position require ß-blocker treatment. The AH patients with S>25% and LF>250 ms2 in horizontal body's position do not require any ACE-Is or ß-blocker treatment. Both drug groups can be used in patients with low values of index S and low power of LF band in HRV spectrum. CONCLUSION: The control of AT can be carried out in AH patients taking into account the individual features of autonomic dysfunction in CVS. Sensitivity and specificity of our approach were 65% and 73%, respectively.
[Mh] Termos MeSH primário: Anti-Hipertensivos/uso terapêutico
Fibrilação Atrial/fisiopatologia
Sistema Nervoso Autônomo/fisiopatologia
Hipertensão/tratamento farmacológico
[Mh] Termos MeSH secundário: Anti-Hipertensivos/administração & dosagem
Atenolol/administração & dosagem
Atenolol/uso terapêutico
Estudos de Coortes
Enalapril/administração & dosagem
Enalapril/uso terapêutico
Feminino
Fosinopril/administração & dosagem
Fosinopril/uso terapêutico
Seres Humanos
Hipertensão/fisiopatologia
Masculino
Metoprolol/administração & dosagem
Metoprolol/uso terapêutico
Meia-Idade
Estudos Prospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antihypertensive Agents); 50VV3VW0TI (Atenolol); 69PN84IO1A (Enalapril); GEB06NHM23 (Metoprolol); R43D2573WO (Fosinopril)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:141231
[Lr] Data última revisão:
141231
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140905
[St] Status:MEDLINE
[do] DOI:10.5152/akd.2014.5107



página 1 de 42 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde